Tenaya Therapeutics, Inc. financial data

Symbol
TNYA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
171 Oyster Point Blvd., Suite 500, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 605 % -22.8%
Debt-to-equity 19.4 % +29.6%
Return On Equity -81 % -32.4%
Return On Assets -67.8 % -27.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78.9M shares +16.2%
Common Stock, Shares, Outstanding 68.3M shares +2.2%
Entity Public Float 272M USD +73.5%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 85.7M shares +16.8%
Weighted Average Number of Shares Outstanding, Diluted 85.7M shares +16.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 93.7M USD -7.8%
General and Administrative Expense 33.3M USD +0.62%
Operating Income (Loss) -127M USD +5.74%
Nonoperating Income (Expense) 6.21M USD +13.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -121M USD +6.56%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -121M USD +6.56%
Earnings Per Share, Basic -1.54 USD/shares +30%
Earnings Per Share, Diluted -1.54 USD/shares +30%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 58.1M USD -23.1%
Marketable Securities, Current 115M USD -29.6%
Cash, Cash Equivalents, and Short-term Investments 99.3M USD -34.5%
Other Assets, Current 1.41M USD
Assets, Current 105M USD -24.4%
Property, Plant and Equipment, Net 39.4M USD -16.2%
Operating Lease, Right-of-Use Asset 13.7M USD +34.8%
Other Assets, Noncurrent 5.06M USD -8.61%
Assets 163M USD -26.1%
Accounts Payable, Current 4.32M USD -49.1%
Accrued Liabilities, Current 9.03M USD +0.49%
Liabilities, Current 16.7M USD -20.1%
Operating Lease, Liability, Noncurrent 12.2M USD +26.4%
Other Liabilities, Noncurrent 266K USD +10.8%
Liabilities 29.2M USD -5.28%
Accumulated Other Comprehensive Income (Loss), Net of Tax -67K USD +79.9%
Retained Earnings (Accumulated Deficit) -465M USD -35.1%
Stockholders' Equity Attributable to Parent 134M USD -29.5%
Liabilities and Equity 163M USD -26.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.7M USD +5.38%
Net Cash Provided by (Used in) Financing Activities 46.8M USD
Net Cash Provided by (Used in) Investing Activities -4.49M USD -156%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 68.3M shares +2.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 13.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 58.6M USD -22.9%
Deferred Tax Assets, Valuation Allowance 101M USD +42.4%
Deferred Tax Assets, Gross 104M USD +41.3%
Operating Lease, Liability 15.6M USD +18.8%
Payments to Acquire Property, Plant, and Equipment 564K USD -10.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -120M USD +6.48%
Lessee, Operating Lease, Liability, to be Paid 19.6M USD +13.7%
Property, Plant and Equipment, Gross 68M USD +1.49%
Operating Lease, Liability, Current 3.36M USD -2.44%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.86M USD +58%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.86M USD -1.25%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure -10.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4M USD -2.79%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.78M USD +172%
Deferred Tax Assets, Operating Loss Carryforwards 52.8M USD +27.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 4.52M USD +43.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.47M USD +3.01%
Operating Lease, Payments 1.33M USD +1.29%
Additional Paid in Capital 599M USD +12.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.16M USD +1.17%
Deferred Tax Assets, Net of Valuation Allowance 3.04M USD +12.8%
Share-based Payment Arrangement, Expense 16.8M USD +22.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%